MENU
+Compare
BPMC
Stock ticker: NASDAQ
AS OF
May 8 closing price
Price
$98.76
Change
-$1.04 (-1.04%)
Capitalization
6.38B

BPMC Blueprint Medicines Corp Forecast, Technical & Fundamental Analysis

Blueprint Medicines Corp is a biopharmaceutical company... Show more

Industry: #Biotechnology
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for BPMC with price predictions
May 07, 2025

Momentum Indicator for BPMC turns positive, indicating new upward trend

BPMC saw its Momentum Indicator move above the 0 level on April 21, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BPMC just turned positive on April 17, 2025. Looking at past instances where BPMC's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

BPMC moved above its 50-day moving average on April 28, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BPMC crossed bullishly above the 50-day moving average on May 02, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BPMC advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BPMC moved out of overbought territory on May 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for BPMC moved below the 200-day moving average on April 04, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BPMC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BPMC broke above its upper Bollinger Band on May 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BPMC entered a downward trend on April 04, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BPMC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.727) is normal, around the industry mean (14.238). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (11.211) is also within normal values, averaging (252.967).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

BPMC is expected to report earnings to fall 4,639.00% to -45 cents per share on July 30

Blueprint Medicines Corp BPMC Stock Earnings Reports
Q2'25
Est.
$-0.45
Q1'25
Beat
by $0.50
Q4'24
Missed
by $0.09
Q3'24
Beat
by $0.07
Q2'24
Beat
by $0.49
The last earnings report on May 01 showed earnings per share of 0 cents, beating the estimate of -49 cents. With 796.70K shares outstanding, the current market capitalization sits at 6.38B.
A.I. Advisor
published General Information

General Information

a developer of cancer therapies that harness the growing understanding of the molecular blueprint of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
45 Sidney Street
Phone
+1 617 374-7580
Employees
655
Web
https://www.blueprintmedicines.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DWAS79.691.60
+2.05%
Invesco Dorsey Wright SmallCap Momt ETF
FTXO30.280.54
+1.82%
First Trust Nasdaq Bank ETF
HEAT25.75N/A
N/A
Touchstone Climate Transition ETF
FIXD43.27-0.28
-0.64%
First Trust TCWOpportunistic Fxd Inc ETF
TSDD33.68-2.22
-6.18%
GraniteShares 2x Short TSLA Daily ETF

BPMC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BPMC has been loosely correlated with ORIC. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BPMC jumps, then ORIC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BPMC
1D Price
Change %
BPMC100%
-1.04%
ORIC - BPMC
44%
Loosely correlated
+13.19%
ELVN - BPMC
42%
Loosely correlated
+1.97%
AXON - BPMC
41%
Loosely correlated
+14.13%
OCUL - BPMC
41%
Loosely correlated
+5.67%
BBIO - BPMC
40%
Loosely correlated
-2.71%
More